Sumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan

MT Newswires Live

03/02

Sumitomo Pharma Co (TYO:4506) unveiled "Boost 2028" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier "Reboot 2027" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.

The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.

Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.

The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2616233610"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616233610\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616233610?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616233610","market":"hk","top_or_hot":-1,"title":"Sumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SMDPY\">Sumitomo Pharma</a> Co (TYO:4506) unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.</p><p>Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.</p><p>The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSumitomo Pharma Sets 10% ROE Goal Under New Boost 2028 Plan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-02 18:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SMDPY\">Sumitomo Pharma</a> Co (TYO:4506) unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.</p><p>The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.</p><p>Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.</p><p>The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROE","symbol_name":"ASTORIA US QUALITY KINGS ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616233610","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616233610","pubTimestamp":1772448296,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sumitomo Pharma Co  unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROE":"ASTORIA US QUALITY KINGS ETF"},"translate_title":"住友制药根据新的Boost 2028计划设定10%的ROE目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROE":1.5},"content_text":"Sumitomo Pharma Co (TYO:4506) unveiled \"Boost 2028\" as its growth strategy for fiscal 2026 through fiscal 2028, revising its earlier \"Reboot 2027\" plan as it seeks to accelerate earnings recovery, according to a Monday filing on the Tokyo Stock Exchange.The company said it expects record core operating profit of 107 billion yen for fiscal 2025 and aims to achieve its previous financial targets ahead of schedule following structural reforms and a rebound in performance.Under Boost 2028, Sumitomo Pharma targets combined sales of more than 350 billion yen in fiscal 2028 from its two flagship drugs, ORGOVYX and GEMTESA. It also aims to deliver return on equity of 10% or more over fiscal 2026 to fiscal 2028, lift its equity ratio above 50% at an early stage and return to positive net cash.The company plans cumulative research and development spending of more than 180 billion yen over the three years, including regenerative medicine and cell therapy operations accounted for under the equity method.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}